TRPC6 and focal segmental glomerulosclerosis: TRPC6 gain-of-function mutations augment angiotensin II–dependent (AngII-dependent) increases in podocyte calcium, causing dysfunction and loss of podocytes and hereditary FSGS (7, 8).